Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. (ANTX) is a clinical-stage biopharmaceutical company developing innovative treatments for serious infectious diseases. This news hub provides investors and stakeholders with timely updates on ANTX's progress in addressing conditions like non-tuberculous mycobacterial (NTM) lung disease through its investigational therapies.
Access authoritative information on clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection features official press releases and verified news about ANTX's drug pipeline, research advancements, and corporate announcements.
Key updates include progress on ANTX's lead oral therapeutic candidate, financial reporting disclosures, and collaborations advancing infectious disease treatment. Bookmark this page to stay informed about critical developments in ANTX's mission to transform patient outcomes through targeted biomedical innovation.
AN2 Therapeutics (Nasdaq: ANTX) reported Q2 2024 financial results and recent business updates. Key points include:
- Cash position: $104.5 million as of June 30, 2024, expected to fund operations through 2027
- Termination of epetraborole Phase 2/3 study in TR-MAC lung disease due to similar sputum culture conversion rates between treatment arms
- Pipeline advancement: Two development programs expected to enter clinical trials in 2025
- Q2 2024 financials: R&D expenses $12.1 million, G&A expenses $3.7 million, net loss $14.4 million
Despite setbacks in the MAC lung disease study, AN2 remains focused on advancing its boron chemistry platform in infectious diseases and oncology.
AN2 Therapeutics (Nasdaq: ANTX) announced that the EBO-301 Phase 2/3 study evaluating epetraborole for treatment-refractory Mycobacterium avium Complex (MAC) lung disease will be discontinued. The Phase 2 part met its primary objective of demonstrating a higher patient-reported outcome (PRO)-based clinical response rate (39.5% vs. placebo 25.0%; p=0.19), but sputum culture conversion at Month 6 was similar between treatment arms (13.2% vs. 10.0%; p=0.64). No significant safety concerns were noted.
The company will shift focus to its boron chemistry platform and other pipeline programs, including Chagas disease and melioidosis. Restructuring and cost savings are expected to extend the cash runway through 2027. Further evaluation of the EBO-301 study results will inform future development of epetraborole for NTM lung disease.
AN2 Therapeutics (Nasdaq: ANTX) released its Q1 2024 financial results and recent business updates. The company is focusing on the Phase 2/3 trial of epetraborole for treatment-refractory Mycobacterium avium Complex (TR-MAC). Phase 2 topline results are expected in August 2024. Phase 3 enrollment is paused due to lower than expected efficacy, not safety issues. R&D expenses rose to $14.7M from $12.0M YoY, while G&A expenses decreased to $3.6M from $4.1M. The net loss increased to $16.6M from $15.3M YoY. Cash reserves stood at $118.1M as of March 31, 2024.
